Month: October 2026

In Labiotech’s deep dive on emerging prostate cancer treatments, the standout innovation comes from Jonas Båtelson, CEO of Curacell, explains that CC‑38 is designed specifically to overcome the immunosuppressive “cold tumor” environment that makes these cancers resistant to immunotherapy. By reviving exhausted T cells and restoring their ability to recognise and attack tumors, CuraCell’s platform aims to turn cold tumors hot and unlock responses where other immunotherapies fail.

The article highlights CuraCell’s ongoing Phase I/IIa trial in Frankfurt and underscores Jonas’s central message: the company has cracked a key challenge in solid‑tumor immunotherapy — revitalising naturally occurring T cells so they can persist, function, and kill cancer cells inside highly suppressive tumor microenvironments.

Read the full article here. 

In the latest Base to Base biotech podcast, Dicot Pharma’s CEO, Elin Trampe tells Jim Cornall how the company is developing LIB‑01, positioned as the first major innovation in erectile dysfunction treatment in 30 years. Unlike Viagra or Cialis, LIB‑01 uses a completely different mechanism of action, enabling treatment for a broader population of men, including those who cannot take PDE5 inhibitors.

Trampe confirms that Dicot has recently received regulatory clearance to begin Phase IIb trials in the US, with EU trials also about to start. The treatment is designed as a three‑dose regimen that provides spontaneous erectile function for up to eight weeks, removing the need for planning around sexual activity and aiming to improve intimacy and quality of life for couples.

Listen to the podcast here. 

Affibody's Fredrik Frejd recently spoke with Clinical Supply Leader about why radiopharmaceutical logistics operate on a knife‑edge. He compared transporting radioactive drugs to “moving melting ice cubes,” where every dose must arrive at precisely the right activity — and any disruption, including a patient missing their appointment, can waste an entire batch.

Frejd outlined how decay profiles dictate everything from manufacturing location to scheduling flexibility. Short half‑lives demand production near trial sites, while longer‑lived isotopes like actinium‑225 allow global shipping but remain in critically short supply. Consistent dosimetry, cross‑border transport rules, and uneven regulatory frameworks add further complexity.

The field now faces a strategic choice: standardised dosing that speeds trials, or personalised dosimetry that could unlock more precise and effective radiotherapeutics. “It’s a delicate balance,” Frejd said — one that will shape how widely patients can access these emerging treatments.

Read the full article here.